Author

Phillip L. Banks

OpenAlex ID: A5065368078

103-OR: LX9211, an Orally-Administered, Non-opioid, AAK1 Inhibitor for Painful Diabetic Peripheral Neuropathy—Results from a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study

2023 · RODICA BUSUI, ANAND PATEL, et al. · Diabetes · 4

1876-LB: Pilavapadin, an Oral, Non-opioid, AAK1 Inhibitor for Diabetic Peripheral Neuropathic Pain (DPNP)—Results from a Phase 2b, Dose-Ranging, Randomized, Multicenter Study

2025 · RODICA POP-BUSUI, SUMA GOPINATHAN, et al. · Diabetes · 1

917-P: Sotagliflozin vs. Empagliflozin or Placebo in Type 2 Diabetes on a DPP-4i +/- Metformin

2024 · ANNE L. PETERS, MARQUETTE B. HARDIN, et al. · Diabetes · 1

244-OR: Sotagliflozin Added to Insulin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes Regardless of Kidney Function

2025 · MARQUETTE B. HARDIN, AMY K. CARROLL, et al. · Diabetes

924-P: Impact of Sotagliflozin, a Dual Sodium–Glucose Cotransporter 1/2 Inhibitor, as Add-on to Inadequately Controlled Basal Insulin–Treated Type 2 Diabetes

2024 · JULIO ROSENSTOCK, AMY K. CARROLL, et al. · Diabetes

272-OR: The Efficacy of Sotagliflozin on Heart-Failure Related Outcomes Is Independent of Baseline A1C

2023 · RAHUL AGGARWAL, DEEPAK L. BHATT, et al. · Diabetes

864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED

2022 · SILVIO E. INZUCCHI, DEEPAK L. BHATT, et al. · Diabetes

Works count: 7

Citation count: 6

H-index: 1

I10-index: